REGENXBIO Presents Positive One Year Data from Phase II ALTI

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Arizona , United States , Rockville , California , San Francisco , American , Steve Pakola , Dana Cormack , Chris Brinzey , Mark Barakat , Peter Kaiser , American Academy Of Ophthalmology , Technology Platform , Cleveland Clinic Lerner College Of Medicine , Nasdaq , Securities Exchange , Exchange Commission , Corporate Communications , Technology Platform Licensees , Ophthalmology Research , Clearside Biomedical Inc , Cole Eye Institute , Diabetic Retinopathy Severity Scale , American Academy , Retinal Consultants , Chief Medical Officer , Safety Summary , Corrected Visual Acuity , Chaney Family Endowed Chair , Cleveland Clinic Lerner College , Clearside Biomedical , Platform Licensees , Securities Act , Securities Exchange Act , Financial Condition ,